mProX™ Human GPR55 Stable Cell Line

Zamith Cunha R, et al. "Endocannabinoid System Receptors at the Hip and Stifle Joints of Middle-Aged ." Animals : an open access journal from MDPI, 2023.
The endocannabinoid system (ECS) has been recognized as a potential therapeutic target in veterinary medicine due to its involvement in various physiological processes such as pain, inflammation, immune function, and neurological function. Modulation of ECS receptors has shown promising results in reducing inflammation, pain, and immune response in animal models, including dogs with osteoarthritis. The current study aimed to examine and compare the presence and distribution of cannabinoid receptor type 1 (CB1R), type 2 (CB2R), and the cannabinoid-related G protein-coupled receptor 55 (GPR55) in the synovial cells of hip and stifle joints of seven dogs without obvious signs of osteoarthritis. Immunofluorescence and Western blot analysis were used to detect the expression of these receptors in synovial tissues collected postmortem. Results showed that CB1R, CB2R, and GPR55 were present in synoviocytes of both hip and stifle joints without significant differences between the two. Macrophages, neutrophils, and vascular cells were also found to express CB2R and GPR55. These findings suggest that targeting the ECS with the use of Cannabis sativa extract may have therapeutic potential for canine arthropathies.
Pubmed: 37760233   DOI: 10.3390/ani13182833

Kollipara R, et al. "Phytocannabinoids Reduce Seizures in Larval Zebrafish and Affect Endocannabinoid ." Biomolecules, 2023.
The effectiveness of cannabis as an anticonvulsant has been demonstrated, and a significant portion of epileptic patients do not achieve satisfactory seizure control with standard treatment. A study was conducted using cannabinoids to treat convulsions induced by pentylenetetrazol in a zebrafish model. The researchers also investigated the impact of these cannabinoids on gene expression and developed a simple assay for assessing their uptake in zebrafish tissues. Results indicated that cannabidiol (CBD), cannabichromene (CBC), and cannabinol (CBN) displayed anticonvulsant effects at low doses without causing sedation, and CBC had the lowest accumulation in larval tissues according to a novel HPLC assay. Furthermore, the anticonvulsant effects of CBD were partially mediated by the Gpr55 receptor. Treatment with endocannabinoids, such as 2-arachidonoylglycerol (2-AG) and anandamide (AEA), resulted in changes to larval movement and gene expression related to metabolism, suggesting that manipulation of endocannabinoid levels may contribute to the anticonvulsant effects of phytocannabinoids.
Pubmed: 37759798   DOI: 10.3390/biom13091398